| 1Folkman J.Antiangiogenesis in cancer therapy-Endostatin and its mechanisms of action[J].Exp Cell Res,2006,312(5):594-607.
2高伟,马静,隋军,等.人血管内皮抑素的研究及治疗进展[J].现代肿瘤医学,2008,16(10):1809-12.
3杨林,王金万,汤仲明,等.重组人血管内皮抑素I期临床研究[J].中国新药杂志,2004,13(6):548-553.
4邓靖宇,何生.血管内皮生长因子和内皮抑素在肝癌抗肿瘤相关血管治疗中的作用[J].中华肝脏病杂志,2005,13(4):313-4.
5Boehle AS,Kurdow R,Schulze M,et al.Human endostatin inhibits growth of hu-man non-small cell lung cancer in a murine xenotransplant model[J].Int J Canc-er,2001,94(3):420-428.
6Bloch W,Huggel K,Sasaki T,et al.The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing[J].FASEB J,2000,14(15):2373-76.
7Isayeva T,Ren C,Ponnazhagan S,et al.Recombinant adeno-associated virus2-me-diated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer[J].Clin Cancer Res,2005,11(2):1342-47.
8周志伟,万德森,王国强,等.血管生成抑制剂YH-16联合氟尿嘧啶抑制结直肠癌肝转移的研究[J].中华胃肠外科杂志,2006,9(2):161-164.
9Perletti G,Concari P,Giardini R,et al.Antitumor activity of endostatin against car-cinogen-induced rat primary mammary tumors[J].Cancer Res,2000,60(7):1793-96.
10Boehm T,Folkman J,Browder T,et al.Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance[J].Nature,1997,390(6658):404-407.
11Kisker O,Becker cm,Prox D,et al.Continuous administration of endostratin by intraperitoneally implanted ostomic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model[J].Cancer,2001,61(20):7669-74.
12Thomas JP,Arzoomanian RZ,Alberti D,et al.Phase I pharmacokinetic and phar-macodynamic study of recombinant human endostatin in patients with advanced solid tumors[J].J Clin Oncol,2003,21(2):223-231.
13Hansma AH,Broxterman HJ,Vander-Horst I,et al.Recombinant human endosta-tin administered as a28-day continuous intravenous infusion,followed by daily subcutaneous injections:a phase I and pharmacokinetic study in patients with ad-vanced cancer[J].Ann Oncol,2005,16(10):1695-1701.
14Eder JP,Supko JG,Clark JW,et al.Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily[J].J Clin Oncol,2002,20(18):3772-84.
15Herbst RS,Hess KR,Tran HT,et al.Phase I study of recombinant human en-dostatin in patients with advanced solid tumors[J].J Clin Oncol,2002,20(18):3792-803.
16Kulke MH,Bergsland EK,Ryan DP,et al.Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors[J].J Clin Oncol,2006,24(22):3555-61.
17杨林,王金万,崔成旭,等.重组人血管内皮抑素YH-16联合用药治疗非小细胞肺癌的多中心Ⅱ期临床试验[J].中国新药杂志,2005,14(2):204-207.
18王金万,孙燕,刘永煜,等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8:283-290.
19秦叔逵,刘秀峰,王琳,等.重组人血管内皮抑素与化疗联合治疗肺外晚期恶性肿瘤的临床研究[J].临床肿瘤学杂志,2007,12(10):827-834.
20刘秀峰,秦叔逵,王琳,等.恩度与化疗联合治疗多种晚期恶性肿瘤的临床观察[J].临床肿瘤学杂志,2007,12(4):142-147.
21袁霞,张东生,马慧敏,等.恩度联合化疗在HER-2阴性乳腺癌肝转移中的临床应用—附5例报告[J].癌症进展杂志,2007,5(6):604-607.
22覃晶,张鹏海,钱新宇,等.重组人血管内皮抑素联合化疗心脏毒性的分析[J].中国肿瘤临床,2008,35(1):12-14. |
